Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents-Reference-Cited by-同舟云学术

Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents

Published:2020-12-04 Issue:5 Volume:56 Page:1144-1150
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Vaxman Iuliana^ORCID,Visram Alissa,Kumar Shaji^ORCID,Dispenzieri Angela^ORCID,Buadi Francis,Dingli David,Lacy Martha,Muchtar Eli^ORCID,Kapoor Prashant,Hogan William^ORCID,Hayman Suzanne,Leung Nelson^ORCID,Gonsalves Wilson,Kourelis Taxiarchis,Warsame Rahma,Berger Tamar,Gertz Morie A.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-020-01159-9.pdf

Reference44 articles.

1. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096–107.

2. Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020;7:e447–e55.

3. Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7:e370–e80.

4. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl J Med. 2019;381:727–38.

5. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548–67.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review;Journal of Geriatric Oncology;2024-04

2. Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?;Hematology/Oncology Clinics of North America;2023-12

3. The obesity paradox in multiple myeloma: A report from Multiple Myeloma Research Foundation (MMRF) dataset;Cancer Medicine;2023-11-06

4. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma;Future Oncology;2023-04

5. Higher Age (≥60 Years) Increases the Risk for Adverse Events during Autologous Hematopoietic Stem Cell Transplantation;Cancers;2023-03-03